# NIH Reporter #1R43AI197630-01

Identification of protective human monoclonal antibodies for passive immunization against Cryptosporidium

**Recipient:** IMMPORT THERAPEUTICS, INC.

**Award Amount:** $300,000.00
**Ceiling:** $300,000.00

**Awarded:** September 09, 2026

**Identifier:** 1R43AI197630-01

The award supports the development of passive immunization vaccines using monoclonal antibodies against Cryptosporidium, focusing on vulnerable populations and employing advanced structural prediction and in vitro testing methods.

### Description

This project aims to develop passive immunity vaccines using high-affinity monoclonal antibodies (mAbs) against Cryptosporidium, a leading cause of diarrhea in infants and elderly populations. The approach involves analyzing maternally transferred antibodies, utilizing AlphaFold structural prediction algorithms to identify optimal mAbs, and testing these candidates with in vitro assays such as invasion neutralization and sporozoite motility inhibition. The strategy addresses a critical need for protection in early life and among vulnerable groups, leveraging advanced structural prediction tools to innovate vaccine and therapy development for cryptosporidiosis and other pathogens.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11315417)